Home » NRDL

Tag Archives: NRDL

DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path

Posted on by — No Comments ↓

We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1]  The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies.  Compared to 2015, trial numbers have steadily Continue reading DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path→

The Economist On China Pharma Going Global

Posted on by — No Comments ↓

There have been several articles on the China Pharma market recently, its development pipeline and the changes to the regulatory environment [1], [2], [3]. They paint a picture of R&D in transition; a provider of services becoming an innovator, a maturing pharma landscape that is increasingly more efficient and business-oriented, with Continue reading The Economist On China Pharma Going Global→